

Cover Story
Regulatory News
By Jacquelyn Cobb and Paul Goldberg
Can a single drug replace a long-established curative, albeit brutal, regimen of chemotherapy, radiation, and surgery?
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - As more people are surviving cancer, we must continue funding bold science

















